Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1223-1231

  Caramés, Marta ^a   Alonso Varona, Ana ^a   García Alonso, Ignacio ^a   Palomares, Teodoro ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

5 fluorouracil; Buthionine SR sulfoximine; Glutathione modulation; Growth factors; L 2 oxothiazolidine 4 carboxylate; Oxaliplatin; SN 38; WiDr colon cancer cells

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BUTHIONINE SULFOXIMINE; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GLUTATHIONE; IRINOTECAN; OXALIPLATIN; SCATTER FACTOR; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; WIDR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GLUTATHIONE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ORGANOPLATINUM COMPOUNDS; PYRROLIDONECARBOXYLIC ACID; THIAZOLIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953802788     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M and Edwards BK: SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008.
2. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Center Ther 1: 227-235, 2002.
3. Rivory LP, Bowles MR, Robert J and Pond SM: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111, 1996.
4. Rougier P: Palliative and adjuvant chemotherapy in colorectal cancer. Eur J Cancer 37: 189-202, 2001.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 355: 1041-1407, 2000.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santero A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
10. Peeters M, Balfour J and Arnold D: Review article: panitumumab, a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 28: 269-281, 2008.
11. Melisi D, Troiani T, Damiano V, Tortora G and Ciardiello F: Therapeutic integration of signal transduction targeting agents and conventional anticancer treatments. Endocr Relat Cancer 11: 51-68, 2004.
12. Palomares T, Caramés M, García-Alonso I and Alonso-Varona A: Glutathione modulation reverses the growth-promoting effect of growth factors, improving the 5-fluorouracil antitumour response in WiDr human colon cancer cell line. Anticancer Res 29: 3957-3965, 2009.
13. Kishida O, Miyazaki Y, Murayama Y, Ogasa M, Miyazaki T, Yamamoto T, Watabe K, Tsutsui S, Kiyohara T, Shimomura I and Shinomura Y: Gefitinib ("Iressa", ZD1839) inhibits SN-38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 55: 393-403, 2005.
14. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N and Nishio K: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108: 464-472, 2004.
15. Thannickal VJ and Fanburg BL: Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279: 1005-1028, 2000.
16. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M and Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
17. Meister A: Glutathione deficiency produced by inhbition of its synthesis, and its reversal: applications in research and therapy. Pharmacol Ther 57: 155-194, 1991.
18. Palomares T, Bilbao P, del Olmo M, Castro B, Calle Y and Alonso-Varona A: In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma. Melanoma Res 9: 233-242, 1999.
19. Bilbao P, del Olmo M, Alonso-Varona A, Castro B, Bilbao J and Palomares T: L-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases. Melanoma Res 12: 17-26, 2002.
20. del Olmo M, Alonso-Varona A, Castro B, Calle Y, Bilbao P and Palomares T: Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases. Melanoma Res 10: 103-112, 2000. (Pubitemid 30256872)
21. del Olmo M, Alonso-Varona A, Castro B, Bilbao P and Palomares T: Cytomodulation of interleukin-2 effect by L-2-oxothiazolidine-4-carboxylate on human malignant melanoma. Cancer Immunol Immunother 55: 948-957, 2006.
22. Bailey HH: L-S, R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111: 239-254, 1998.
23. Rose DM, Hochwald SN, Harrison LE and Burt M: Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat. J Surg Res 62: 224-228, 1996.
24. Golfinopoulus V, Salanti G, Pavlidis N and Ioannidis JP: Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8: 898-811, 2007.
25. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF and Jodrell DI: Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Research 9: 2856-2865, 2003.
26. Hwang IT, Chung YM, Kim JJ, Chung JS, Kim BS, Kim HJ. Kim JS and Yoo YD: Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun 359: 304-310, 2007.
27. Boubakari, Bracht K, Neumann C, Grunert R and Bednarski PJ: No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes. Arch Pharm 337: 668-671, 2004.
28. Yoshida A, Takemura H, Inoue H, Miyashita T and Ueda T: Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res 66: 5772-5780, 2006.
29. Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY and Chow KC: HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol 38: 559-565, 2008.
30. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE and Lev D: Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 66: 8770-8778, 2006.
31. Schmidt M and Lichtner RB: EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat 5: 11-18, 2002.
32. Allendorf J, Ippagunta N and Emond J: Management of liver metastases: new horizonts for biologically based therapy. J Surg Res 117: 144-153, 2004.
33. García-Alonso I, Palomares T, Alonso A, Echenique-Elizondo M, Caramés J, Castro B and Méndez J: Effect of liver resection on the progression and growth of rhabdomyosarcoma metastases in a rat model. J Surg Res 148: 185-190, 2008.
34. Vigeneron A, Gamelin E and Coqueret O: The EGFR-STAT3 oncogenic pathway up regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res 65: 815-825, 2008.
35. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S et al: Role of NF kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24: 1749-1766, 2005.
36. Sethi G and Aggarwal BB: Role of NF-kappaB and NF-kappaB-regulated gene products in chemoresistance and radioresistence. Curr Cancer Ther Rev 2: 115-125, 2006.
37. Gamcsik MP, Kasibhatla MS, Adams DJ, Flowers JL, Colvin OM, Manikumar G, Mansukh W, Wall ME, Kohlhagen G and Pommier Y: Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. Mol Cancer Ther 1: 11-20, 2001.
38. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER and MacKay SL: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120: 178-188, 2004.
39. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M and Peyron JF: Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 98: 335-344, 2008.